A phase II trial of docetaxel/prednisone in combination with sargramostim as treatment for hormone-refractory prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 10 May 2012
At a glance
- Drugs Docetaxel; Prednisone; Sargramostim
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Dec 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Aug 2008 Planned end date (Dec 2008) added as reported by ClinicalTrials.gov.